Ignite Creation Date:
2024-05-06 @ 9:10 AM
Last Modification Date:
2024-10-26 @ 12:11 PM
Study NCT ID:
NCT02919735
Status:
COMPLETED
Last Update Posted:
2019-08-13
First Post:
2016-09-18
Brief Title:
Efficacy Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia Controlled Study ELAN
Sponsor:
Legacy Healthcare SA
Organization:
Legacy Healthcare SA
Study Overview
Official Title:
A Randomized Double Blind Single Center Controlled Study to Compare the Efficacy Safety and Tolerability of CG 428 Cutaneous Solution With Placebo on Alopecia in Cancer Female Patients Under Chemotherapy
Status:
COMPLETED
Status Verified Date:
2019-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ELAN
Brief Summary:
Phase II clinical trial
Detailed Description:
The aim of this trial is to compare the degree of efficacy safety and tolerability of CG 428 cutaneous solution versus placebo on prevention of chemotherapy induced alopecia CIA in female patients with metastatic cancer treated with selected regimens inducing alopecia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None